The one-time offer — available through June 30 — is intended for patients who were taking copycat, or compounded, versions of Wegovy. After that, it will cost $499 a month for self-paying customers.
On Thursday, pharmacies were supposed to stop making the copies of the medications that had become popular during shortages of the brand-name drugs.
“We are doubling down on our commitment to accessibility, availability, and affordability of authentic, FDA-approved ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
